PSYCHEDELX Is a privately held, pre-clinical-stage pharmaceutical company focused on the development of psychotropic drug products that represent a transformation in the targeting of depression, PTSD, anxiety, and other psychiatric conditions.
Our team has partnered with academic founders and key opinion leaders to identify synthetic therapeutics, including the first drug being designed to significantly advance our understanding of treating mental health.